Pacira Pharmaceuticals, Inc. (PCRX) Position Raised by Sei Investments Co.

Sei Investments Co. boosted its stake in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 75.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 40,495 shares of the company’s stock after buying an additional 17,388 shares during the period. Sei Investments Co. owned approximately 0.10% of Pacira Pharmaceuticals worth $1,932,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Suffolk Capital Management LLC increased its stake in shares of Pacira Pharmaceuticals by 8.2% in the second quarter. Suffolk Capital Management LLC now owns 32,360 shares of the company’s stock valued at $1,544,000 after buying an additional 2,457 shares during the period. Lebenthal Lisanti Capital Growth LLC increased its stake in shares of Pacira Pharmaceuticals by 61.8% in the second quarter. Lebenthal Lisanti Capital Growth LLC now owns 16,700 shares of the company’s stock worth $797,000 after buying an additional 6,380 shares during the last quarter. Schnieders Capital Management LLC bought a new stake in shares of Pacira Pharmaceuticals during the second quarter worth about $201,000. Benjamin F. Edwards & Company Inc. increased its stake in shares of Pacira Pharmaceuticals by 12.2% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock worth $133,000 after buying an additional 303 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Pacira Pharmaceuticals by 3,599.8% in the second quarter. Russell Investments Group Ltd. now owns 283,513 shares of the company’s stock worth $13,524,000 after buying an additional 275,850 shares during the last quarter.

Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) opened at 35.75 on Friday. The stock’s market cap is $1.44 billion. The company has a 50 day moving average of $41.49 and a 200-day moving average of $45.06. Pacira Pharmaceuticals, Inc. has a 12-month low of $29.95 and a 12-month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.06. The firm had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the firm earned $0.21 EPS. Equities analysts forecast that Pacira Pharmaceuticals, Inc. will post ($0.16) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “[[title]]” was originally published by [[site]] and is owned by of [[site]]. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at [[permalink]].

A number of brokerages have recently issued reports on PCRX. Royal Bank Of Canada set a $58.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price target on shares of Pacira Pharmaceuticals in a report on Monday, May 15th. Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a report on Friday, July 14th. Wedbush reaffirmed an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, July 19th. Finally, Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $53.92.

In other news, VP Lauren Bullaro Riker sold 601 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $26,035.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Scott Braunstein sold 768 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $33,269.76. Following the completion of the transaction, the senior vice president now directly owns 9,982 shares in the company, valued at approximately $432,420.24. The disclosure for this sale can be found here. In the last three months, insiders sold 42,913 shares of company stock worth $1,628,016. Corporate insiders own 6.60% of the company’s stock.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).